Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2023-07-13 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2023年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2023, indicating expected net profit and growth percentages compared to the previous year. It explicitly states that the data is preliminary and unaudited, and that the final accurate financial data will be disclosed in the formal half-year report. The document is short (1187 characters) and serves as an announcement of expected financial results rather than a comprehensive financial report with actual financial statements or detailed analysis. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only.
2023-07-13 Chinese
普莱柯关于购买、出售资产暨关联交易的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the purchase and sale of assets and related party transactions by 普莱柯生物工程股份有限公司. It includes extensive valuation methods, financial forecasts, and transaction pricing explanations related to equity acquisitions and disposals. The content focuses on asset purchase, sale, and related party transaction disclosures rather than a full annual or interim financial report, earnings release, or management discussion. It is not a simple announcement of a report publication but a substantive disclosure about capital transactions involving asset purchases and sales. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including asset acquisitions and disposals.
2023-07-04 Chinese
世纪萌邦（上海）信息技术有限公司审计报告及财务报表
Regulatory Filings
2023-06-30 Chinese
独立董事关于购买、出售资产暨关联交易事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on a purchase, sale of assets, and related party transaction matter. It references relevant laws and regulations and confirms the fairness and legality of the transaction. It is not a full financial report, earnings release, or management discussion. It is a formal opinion related to a specific transaction and governance compliance. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement related to corporate governance and transaction approval, not a full report or announcement of voting results.
2023-06-30 Chinese
普莱柯关于购买、出售资产暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the purchase and sale of assets and related party transactions by 普莱柯生物工程股份有限公司. It includes descriptions of the transaction parties, asset valuations, financial data of the involved companies, approvals by the board and supervisory committees, and independent opinions. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about a corporate transaction involving asset purchases and sales, specifically related party transactions. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including asset acquisitions and disposals. The document length (9424 characters) and content confirm it is a full announcement, not a brief notice or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-06-30 Chinese
洛阳乐宠健康科技有限公司审计报告及财务报表
Regulatory Filings
2023-06-30 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.